Skip to main content

Table 2 Univariable and multivariable logistic and Cox regression analyses of risk factors associated with RR, PFS, and OS

From: Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

  RR* PFS# OS$
  Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis
  OR (95% CI) p-value OR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Heng Prognostic Score
 Low Reference   Reference   Reference   Reference   Reference   Reference  
 Int/High^ 0.500 (0.124,1.973) 0.319 0.553 (0.130,2.322) 0.414 0.779 (0.379,1.6) 0.496 0.892 (0.433,1.837) 0.757 0.514 (0.182,1.451) 0.201 0.559 (0.197,1.585) 0.274
Duration of prior anti-VEGF Therapies
 < 6 Months Reference   Reference   Reference   Reference   Reference   Reference  
 ≥ 6 Months 2.200 (0.613,8.678) 0.237 2.362 (0.627,9.979) 0.216 2.015 (1.046,3.883) 0.048 2.288 (1.094,4.785) 0.028 2.869 (0.9,9.141) 0.063 2.913 (0.904,9.388) 0.073
Pretherapy NLR
 < 3 Reference   Reference   Reference   Reference   Reference   Reference  
 ≥ 3 2.567 (0.717,10.16) 0.158 2.538 (0.674,10.57) 0.178 2.67 (1.343,5.308) 0.004 2.937 (1.444,5.972) 0.003 3.977 (1.227,12.889) 0.014 4.01 (1.189,13.524) 0.025
  1. ^, Intermediate and high; *, PD1/PDL1 response rate to progression disease and non-response; #, progression-free survival; $, overall survival